237 related articles for article (PubMed ID: 27521362)
1. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.
Adler SP; Manganello AM; Lee R; McVoy MA; Nixon DE; Plotkin S; Mocarski E; Cox JH; Fast PE; Nesterenko PA; Murray SE; Hill AB; Kemble G
J Infect Dis; 2016 Nov; 214(9):1341-1348. PubMed ID: 27521362
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
[TBL] [Abstract][Full Text] [Related]
3. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus.
Quinnan GV; Delery M; Rook AH; Frederick WR; Epstein JS; Manischewitz JF; Jackson L; Ramsey KM; Mittal K; Plotkin SA
Ann Intern Med; 1984 Oct; 101(4):478-83. PubMed ID: 6089634
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains Towne and Toledo.
Suárez NM; Lau B; Kemble GM; Lee R; Mocarski ES; Wilkinson GWG; Adler SP; McVoy MA; Davison AJ
Virus Genes; 2017 Aug; 53(4):650-655. PubMed ID: 28391502
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
7. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
[TBL] [Abstract][Full Text] [Related]
8. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
Gerna G; Lilleri D
New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
[TBL] [Abstract][Full Text] [Related]
11. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
12. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.
Adler SP; Hempfling SH; Starr SE; Plotkin SA; Riddell S
Pediatr Infect Dis J; 1998 Mar; 17(3):200-6. PubMed ID: 9535246
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
[TBL] [Abstract][Full Text] [Related]
15. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
16. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
[TBL] [Abstract][Full Text] [Related]
17. Delayed type hypersensitivity to human cytomegalovirus.
Gupta R; Gonczol E; Manning ML; Starr S; Johnson B; Murphy GF; Plotkin SA
J Med Virol; 1993 Feb; 39(2):109-17. PubMed ID: 8387567
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
[No Abstract] [Full Text] [Related]
19. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
[TBL] [Abstract][Full Text] [Related]
20. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
Jacobson MA; Adler SP; Sinclair E; Black D; Smith A; Chu A; Moss RB; Wloch MK
Vaccine; 2009 Mar; 27(10):1540-8. PubMed ID: 19168107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
